{
    "nctId": "NCT01660776",
    "briefTitle": "BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology",
    "officialTitle": "BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology",
    "overallStatus": "COMPLETED",
    "conditions": "Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma, Metastatic Breastcancer, Non-small Cell Lung Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 105,
    "primaryOutcomeMeasure": "Description of one or several blood cell types producing soluble PD-L1 in DLBCL, metastatic breast cancer, Hodgkin's lymphoma and non-small cell lung cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\nGeneral inclusion criteria :\n\n* Age \u2265 18 years and \u2264 75 years,\n* Life expectancy more than 4 months\n* Signed informed consent obtained\n* Social security affiliation is mandatory\n* Non previously treated (even by corticotherapy),\n* HIV negative, HBs negative, HCV negative\n\nInclusion criteria for DLBCL patients :\n\n* A biopsy proven diagnosis of de novo DLBCL according to the current WHO criteria,\n* Immunohistochemistry for GCB/nonGC classification according to Hans' algorithm\n* Patients with advanced-stage disease defined as Ann Arbor stages III or IV, or stages I or II with bulky disease (\\>7cm)\n\nInclusion criteria for non-small cell lung cancer patients :\n\n* A biopsy proven diagnosis of de novo non-small cell lung cancer (all stages) according to the current WHO criteria\n\nInclusion criteria for Hodgkin's lymphoma patients :\n\n* A biopsy proven diagnosis of Hodgkin's lymphoma according to the current WHO criteria\n\nInclusion criteria for metastatic breast cancer or with lymph node involvement :\n\n* A biopsy proven diagnosis infiltrating lobular or ductal breast carcinoma\n* with lymph node involvement or metastasis\n\nInclusion criteria for patients with immune thrombocytopenia (ITP) :\n\n* Primary ITP was defined by the IWG as a platelet count less than 100 G/L in the absence of other causes or disorders that may be associated with thrombocytopenia.\n* Bone marrow examination excluding a central aetiology of thrombocytopenia\n\nInclusion criteria for healthy volunteers :\n\n- Inclusion criteria for blood donation according to the Etablissement Fran\u00e7ais du Sang (EFS) criteria\n\nExclusion Criteria:\n\nGeneral non-inclusion criteria :\n\n* Age \\< 18 years et \\> 75 years,\n* Pregnant women,\n* Person legally involved in a case\n* No social security affiliation\n* Signed informed consent not obtained,\n* Preliminary treatment (even corticoid treatment).\n* HIV positive, HBs positive, HCV positive\n\nNon-inclusion criteria for DLBCL patients :\n\n* Lymphoma other than DLBCL,\n* Transformation of a low grade lymphoma to a high grade lymphoma (DLBCL),\n* Extranodal marginal zone lymphoma of MALT lymphoma,\n* Post-transplant lymphoproliferative disorders,\n* Lymphoblastic lymphoma,\n* Burkitt's lymphoma,\n* Carcinoma or history of carcinoma except in situ cervical carcinoma.\n\nNon-inclusion criteria for non-small cell lung cancer patients : None\n\nNon-inclusion criteria for Hodgkin patients :\n\n- Non Hodgkin's lymphoma\n\nNon-inclusion criteria for metastatic breast cancer or with lymph node involvement :\n\n* Carcinoma other than infiltrating lobular or ductal breast carcinoma\n* Chemotherapy in 30 days preceding the inclusion\n* Hormonotherapy in 7 days preceding the inclusion\n* Carcinoma or history of carcinoma except in situ cervical carcinoma.\n* Hemoglobin level \\< 10g/dl\n\nNon-inclusion criteria for patients with immune thrombocytopenia (ITP) :\n\n- Central aetiology of the thrombocytopenia\n\nNon-inclusion criteria for healthy volunteers :\n\n- Exclusion criteria for blood donation according to the Etablissement Fran\u00e7ais du Sang (EFS) criteria",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}